ARCHIVES

Niederhuber Says Resignation “Pro Forma,” Hopes To Stay As Director Or Lab Chief.

This article is from The Cancer Letter archive.

Vol. 34 No. 46 | December 19, 2008

Download PDF Visit The Full Archive

Related Articles

DES-Breast Cancer Risk Studies Concept approved

March 7, 1986

Schmidt Already Working For NIH Despite His Opposition To Kennedy’s New Research Panel

April 5, 1974

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

NCAB, President’s Cancer Panel honor the late Paul Calabresi.

June 11, 2004

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

November 2, 2007